Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer

Clinical and Translational Oncology

Volumn 11, Issue 11, 2009, Pages 737-747

  García Sáenz, Jose A ^a   Sastre, Javier ^a   Díaz Rubio García, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

B RAF; Cetuximab; Colorectal cancer; KRAS wild type; Panitumumab

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; JANUS KINASE; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STAT PROTEIN;

AMINO ACID SUBSTITUTION; CANCER SURVIVAL; CLINICAL TRIAL; CODON; COLORECTAL CANCER; DRUG ERUPTION; DRUG RESPONSE; GENE MUTATION; HUMAN; LOADING DRUG DOSE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 73449145113     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0436-5     Document Type: Review

References (107)

1. E. Winer J. Gralow L. Diller, et al. 2009 Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening: a report from the American Society of Clinical Oncology J Clin Oncol 27 812 826 19103723 10.1200/JCO.2008.21.2134
2. J. Cassidy S. Clarke E. Díaz-Rubio, et al. 2008 Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006 2012 1:CAS:528:DC%2BD1cXlvFaqs7s%3D 18421053 10.1200/JCO.2007.14.9898
3. E. Díaz-Rubio J. Tabernero A. Gómez-España, et al. 2007 Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial J Clin Oncol 20 4224 4230 10.1200/JCO.2006.09.8467 1:CAS:528:DC%2BD2sXhtFyis7vL (Pubitemid 47548562)
4. L.B. Saltz S. Clarke E. Díaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 18421054 10.1200/JCO.2007.14.9930
5. L.B. Saltz J.V. Cox C. Blanke, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 914 1:CAS:528:DC%2BD3cXntFOkt7Y%3D 11006366 10.1056/ NEJM200009283431302 (Pubitemid 30727802)
6. L.G. Presta H. Chen S.J. O'Connor, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 1:CAS:528: DyaK2sXmslKqtLg%3D 9377574
7. R. Bianco G. Daniele F. Ciardiello G. Tortora 2005 Monoclonal antibodies targeting the epidermal growth factor receptor Curr Drug Targets 6 275 287 1:CAS:528:DC%2BD2MXktlansb0%3D 15857288 10.2174/1389450053765842 (Pubitemid 40667795)
8. S. Eggstein G. Manthey T. Hirsch, et al. 1996 Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas Dig Dis Sci 41 1069 1075 1:STN:280:DyaK283lvVylsg%3D%3D 8654136 10.1007/BF02088221 (Pubitemid 26227877)
9. D.S. Salomon R. Brandt F. Ciardello N. Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D 7612182 10.1016/1040-8428(94) 00144-I
10. A. Citri Y. Yarden 2006 EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 505 516 1:CAS:528:DC%2BD28Xms1OhsLc%3D 16829981 10.1038/nrm1962 (Pubitemid 44036456)
11. J. Mendelson J. Baselga 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2787 2799 10.1200/JCO.2003.01.504 1:CAS:528:DC%2BD2cXptlCktbo%3D (Pubitemid 46606324)
12. N.H. Hynes H.A. Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354 1:CAS:528:DC%2BD2MXjslertb0%3D 15864276 10.1038/nrc1609 (Pubitemid 40637826)
13. N.S. Goldstein M. Armin 2001 Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer 92 1331 1346 1:STN:280:DC%2BD3Mritl2nsg%3D%3D 11571750 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M (Pubitemid 32861685)
14. J.P. Spano R. Fagard J.C. Soria 2005 Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspective Ann Oncol 16 189 194 1:STN:280:DC%2BD2M%2FjvFyjtA%3D%3D 15668269 10.1093/annonc/mdi057 (Pubitemid 40309295)
15. F. Ciardello G. Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 10.1056/NEJMra0707704
16. S. Li K.R. Schmitz P.D. Jeffrey, et al. 2005 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 301 311 1:CAS:528:DC%2BD2MXjvFSkurk%3D 15837620 10.1016/j.ccr.2005.03.003 (Pubitemid 40544648)
17. L. Saltz N. Meropol P. Loeherer, et al. 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 1:CAS:528:DC%2BD2cXpsVGktLw%3D 14993230 10.1200/JCO.2004.10.182 (Pubitemid 41079832)
18. H.J. Lenz E. Van Cutsem S. Khambata-Ford, et al. 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines J Clin Oncol 24 4914 4921 1:CAS:528:DC%2BD28Xht1eiu73K 17050875 10.1200/JCO.2006.06.7595 (Pubitemid 46630920)
19. D. Cunningham Y. Humblet S. Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer N Engl J Med 351 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 10.1056/NEJMoa033025 (Pubitemid 38944402)
20. C. Eng J. Maurel W. Scheithauer, et al. 2007 Impact of quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial J Clin Oncol 25s A4003
21. D.J. Jonker C.J. O'Callaghan C.S. Karapetis, et al. 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 1:CAS:528:DC%2BD2sXhtlWis7rI 18003960 10.1056/NEJMoa071834 (Pubitemid 350106711)
22. K. Chung J. Shia N. Kemeny, et al. 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 1:CAS:528:DC%2BD2MXjt1Ckuro%3D 15677699 10.1200/JCO.2005.08.037 (Pubitemid 46211358)
23. E. Van Cutsem M. Peeters S. Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer J Clin Oncol 25 1658 1664 17470858 10.1200/JCO.2006.08.1620 1:CAS:528: DC%2BD2sXlvFyktLc%3D (Pubitemid 46797944)
24. E. Van Cutsem S. Siena Y. Humblet, et al. 2008 An open-label, single arm study assessing safety and efficacy of panitumumab in patients with mCRC refractory to standard chemotherapy Ann Oncol 19 92 98 17785764 10.1093/annonc/mdm399
25. G. Folprecht T. Gruenberger J.T. Hartmann, et al. 2008 Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study) Ann Oncol 19 viii168 A510
26. J. Tabernero E. Van Cutsem E. Díaz-Rubio, et al. 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232 1:CAS:528:DC%2BD2sXhsVKnsbzI 18024868 10.1200/JCO.2007.13.2183 (Pubitemid 350232254)
27. E. Van Cutsem C.H. Köhne E. Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 19339720 10.1056/NEJMoa0805019
28. H.J. Andreyev A.R. Norman D. Cunningham, et al. 1998 Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 675 684 1:CAS:528:DyaK1cXjtlSiu7s%3D 9586664 10.1093/jnci/90.9.675
29. W.V. Kastrinakis N. Ramchuren M. Maggard, et al. 1995 KRAS status does not predict successful hepatic resection of colorectal cancer metastasis Arch Surg 130 9 14 1:STN:280:DyaK2M7gtVyktQ%3D%3D 7802584
30. H. Petrowsky I. Sturm O. Graubitz, et al. 2001 Relevance of Ki-67 antigen expression and KRAS mutation in colorectal liver metastases Eur J Surg Oncol 27 80 87 1:STN:280:DC%2BD3M7osFWksA%3D%3D 11237496 10.1053/ejso.2000.1029 (Pubitemid 32229699)
31. A. Lièvre J.B. Bachet D. Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 16618717 10.1158/0008-5472.CAN-06-0191
32. A. Lièvre J.B. Bachet V. Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 18202412 10.1200/JCO.2007.12.5906 1:CAS:528:DC%2BD1cXitVGntLc%3D (Pubitemid 351171687)
33. S. Khambata-Ford C. Garret N. Meropol, et al. 2007 Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 1:CAS:528:DC%2BD2sXhtVWqs7rF 17664471 10.1200/JCO.2006.10.5437 (Pubitemid 47325606)
34. R.G. Amado M. Wolf M. Peeters, et al. 2008 Wildtype KRAS is required for panitumumab efficacy in patients with metastatic cancer J Clin Oncol 26 1626 1634 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791 10.1200/JCO.2007.14.7116
35. C. Karapetis S. Khambata-Ford D. Jonker, et al. 2008 KRAS mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 1:CAS:528:DC%2BD1cXht12nu77J 18946061 10.1056/NEJMoa0804385
36. F. Di Fiore E. Van Cutsem P. Laurent-Puig, et al. 2008 Role of KRAS mutation in predicting response, progression-free survival and overall survival in irinotecan-refractory patients with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series J Clin Oncol 26s A4035
37. W. De Roock H. Piessevaux J. De Schutter, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 17998284 10.1093/annonc/mdm496 (Pubitemid 351325672)
38. C. Bokemeyer I. Bondarenko J. Hartmann, et al. 2008 KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: the OPUS experience J Clin Oncol 26s A4000
39. C. Bokemeyer I. Bondarenko A. Makhson, et al. 2009 Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 1:CAS:528:DC%2BD1MXjsVCjsrk%3D 19114683 10.1200/JCO.2008.20.8397
40. G. Folprecht M.P. Lutz P. Schöffski, et al. 2006 Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 450 456 1:STN:280: DC%2BD287ht1Olug%3D%3D 16303861 10.1093/annonc/mdj084 (Pubitemid 43329582)
41. J.R. Hecht E. Mitchell T. Chidiac, et al. 2009 A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone in metastatic colorectal cancer J Clin Oncol 27 672 680 1:CAS:528:DC%2BD1MXjsVCjs74%3D 19114685 10.1200/JCO.2008.19.8135
42. C.J. Punt J. Tol C.J. Rodenburg, et al. 2008 Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) J Clin Oncol 26s A4011
43. J. Tol M. Koopman A. Cats, et al. 2009 Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer N Engl J Med 360 563 572 1:CAS:528:DC%2BD1MXhsFyitrw%3D 19196673 10.1056/NEJMoa0808268
44. C.D. Blanke 2009 Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may J Clin Oncol 27 655 658 19114682 10.1200/JCO.2008.21.2522
45. R.J. Mayer 2009 Targeted therapy for advancer colorectal cancer. More is not always better N Engl J Med 360 623 625 1:CAS:528:DC%2BD1MXhsFyhsrg%3D 19196680 10.1056/NEJMe0809343
46. J.H.J.M. Van Krieken A. Jung T. Kirchner, et al. 2008 KRAS mutation testing for predicting response to antiEGFR therapy for colorectal carcinoma: proposal for an European quality assurance program Virchows Arch 453 417 431 18802721 10.1007/s00428-008-0665-y 1:CAS:528:DC%2BD1cXht1KgtrfP
47. R. Wong D. Cunningham 2008 Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies J Clin Oncol 26 5668 5670 1:CAS:528:DC%2BD1MXotFemsg%3D%3D 19001346 10.1200/JCO.2008.19.5024
48. J. Baselga N. Rosen 2008 Determinants of RA-Sistance to Anti-Epidermal growth factor receptor agents J Clin Oncol 26 1582 1584 18316790 10.1200/JCO.2007.15.3700
49. F.J. Ramos J. Tabernero 2008 Biomarkers in colorectal cancer Cancer Chemother Rev 4 194 204
50. J. Arribas J. Baselga 2005 Who will benefit from treatment against EGFR? Lancet Oncol 6 257 258 15863372 10.1016/S1470-2045(05)70142-X (Pubitemid 40590246)
51. S. Tejpar M. Peeters Y. Humblet, et al. 2007 Phase I/II study of cetuximab doseescalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab Standard dose treatment (EVEREST): Pharmacokinetic, pharmacodynamic and efficacy data J Clin Oncol 25s A4037
52. S. Tejpar M. Peeters Y. Humblet, et al. 2008 Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan- refractory metastatic colorectal cancer, treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) J Clin Oncol 26s A4001
53. C.J.O. O'Callaghan D. Tu S. Karapetis, et al. 2008 The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17 J Clin Oncol 26s A4130
54. H.J. Lenz R.J. Mayer P.J. Gold, et al. 2004 Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin J Clin Oncol 23s A3510
55. L. Saltz 2005 Epidermal growth factor receptornegative colorectal cancer: Is there truly such and entity? Clin Colorectal Cancer 5s 98 100 10.3816/CCC.2005.s.013
56. N.J. Meropol 2005 Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target J Clin Oncol 23 1791 1793 1:CAS:528:DC%2BD2MXjt1Ckur0%3D 15677698 10.1200/JCO.2005.10.951 (Pubitemid 46211354)
57. A.M. Valentini M. Pirelli M.L. Carusso 2008 EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin Mol Ther 10 124 131 1:CAS:528: DC%2BD1cXlsVentb0%3D 18386224
58. F. Penault-Llorca A. Cayre L. Arnauld, et al. 2006 Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep 16 1173 1179 17089034
59. M. Francoual M.C. Etienne-Grimaldi J.L. Fomento, et al. 2006 EGFR in colorectal cancer: more than a simple receptor Ann Oncol 17 962 967 1:STN:280:DC%2BD283nslegug%3D%3D 16524971 10.1093/annonc/mdl037 (Pubitemid 43778987)
60. J. Hecht E. Mitcell J. Baranda, et al. 2006 Panitumumab antitumor activity in patients with metastatic colorectal cancer expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFR) J Clin Oncol 24s A3547
61. S. Van Schaeybroeck A. Karaiskou-MacCaul D. Kelly, et al. 2005 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy Clin Cancer Res 11 7480 7489 16243822 10.1158/1078-0432.CCR-05-0328 1:CAS:528:DC%2BD2MXhtFartbvF (Pubitemid 41507709)
62. N. Personeni A. Hendlisz J. Gallez, et al. 2005 Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer Semin Oncol 32s 59 62 10.1053/j.seminoncol.2005.04.029 1:CAS:528:DC%2BD28XhtFChu70%3D (Pubitemid 43080918)
63. P.A. Janne J.A. Engelman B.E. Johnson 2005 Epidermal growth factor receptor mutations in nonsmall-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 3227 3234 1:CAS:528:DC%2BD2MXltVWis70%3D 15886310 10.1200/JCO.2005.09.985 (Pubitemid 46211347)
64. Z. Tsuchihashi S. Khambata-Frd N. Hanna, et al. 2005 Responsiveness to cetuximab without mutations in EGFR N Engl J Med 353 208 209 1:CAS:528:DC%2BD2MXmtFGnsrY%3D 16014894 10.1056/NEJM200507143530218 (Pubitemid 41058356)
65. M. Moroni S. Veronese S. Benevenuti, et al. 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279 286 1:CAS:528:DC%2BD2MXjs1Krsb8%3D 15863375 10.1016/S1470-2045(05)70102-9 (Pubitemid 40590264)
66. A. Sartore-Bianchi M. Moroni S. Veronese, et al. 2007 Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with Panitumumab J Clin Oncol 25 3238 3245 1:CAS:528: DC%2BD2sXhtVWqs7vN 17664472 10.1200/JCO.2007.11.5956 (Pubitemid 47325607)
67. N. Personeni S. Fieuws H. Piessevaux, et al. 2008 Clinical usefulness of EGFR copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 5869 5876 1:CAS:528:DC%2BD1cXhtFaitrjP 18794099 10.1158/1078-0432.CCR-08-0449
68. N. Personeni H. Piessevaux S. Fieuws, et al. 2008 Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab J Clin Oncol 26s A11093
69. F. Capuzzo G. Finocchiaro E. Rossi, et al. 2008 EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 717 723 10.1093/annonc/mdm492
70. F. Capuzzo M. Varela-Garcia G. Finocchiaro, et al. 2008 Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Br J Cancer 99 83 89 10.1038/sj.bjc.6604439 1:CAS:528:DC%2BD1cXnvFeru7Y%3D (Pubitemid 351920237)
71. A. Mancuso L. Leone F. Vigna, et al. 2008 EGFR, DCC and KRAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer J Clin Oncol 26S A4128
72. A. Italiano P. Follana F.X. Caroli, et al. 2008 Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number Ann Surg Oncol 15 649 654 17987340 10.1245/s10434-007-9667-2
73. G. Milano M.C. Etienne-Grimaldi L. Dahan, et al. 2008 Epidermal growth factor receptor (EGFR) status and KRAS mutations in colorectal cancer Ann Oncol 19 2033 2038 1:STN:280:DC%2BD1cjlsFeisA%3D%3D 18632722 10.1093/annonc/mdn416
74. A. Goncalvez S. Esteyries B. Taylor-Smedra, et al. 2008 A polymorphism of EGFR domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximabbased treatment BMJ Cancer 8 1 11 10.1186/1471-2407-8-1 1:CAS:528:DC%2BD1cXlt1Ons7s%3D (Pubitemid 351279966)
75. W. Liu X. Wu W. Zhang, et al. 2007 Relationship of EGFR mutations, expression, amplification and polymorphisms to epidermal growth receptor inhibitors in the NC160 cell lines Clin Cancer Res 15 6788 6795 10.1158/1078-0432.CCR-07-0547 1:CAS:528:DC%2BD2sXhtlSmu7fJ (Pubitemid 350206817)
76. S. Puyo V. Le Morvan J. Robert 2008 Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro Mol Diagn Ther 12 225 234 1:CAS:528:DC%2BD1cXhtFWhsrzP 18652519
77. E. Carcereny S. Castellvi-Bel V. Alonso, et al. 2008 EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer treated with cetuximab and panitumumab J Clin Oncol 26s A4124
78. T. Nishimura A. Andoh O. Inatomi, et al. 2008 Amphiregulin and epiregulin expression in neoplastic and inflammatory lesions in the colon Oncol Rep 19 105 110 18097582
79. F. Yotsumoto H. Yagi S.O. Suzuki, et al. 2008 Validation of HB-EGF and amphiregulin as targets for human cancer therapy Biochem Biophys Res Commun 365 555 561 1:CAS:528:DC%2BD2sXhtlyrsbjF 18023415 10.1016/j.bbrc.2007.11.015 (Pubitemid 350181687)
80. Tejpar S, De Roock W, Biesmans B et al (2008) High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. ASCO Gastrointestinal Cancers Symposium a411
81. J.B. Baker D. Dutta T. Watson, et al. 2008 Evaluation of tumor gene expression and KRAS mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer J Clin Oncol 26s A3512
82. L. Barault N. Veyrie V. Jooste, et al. 2008 Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2255 2259 1:CAS:528:DC%2BD1cXkslynsb4%3D 18224685 10.1002/ijc.23388 (Pubitemid 351542328)
83. Y.H. Tan Y. Liu K.W. Eu, et al. 2008 Detection of B-RAF V600E mutation by pyrosequencing Pathology 40 295 298 1:CAS:528:DC%2BD1cXlt1Shsrw%3D 18428050 10.1080/00313020801911512 (Pubitemid 351563933)
84. D. Calistri C. Rengucci I. Seymour, et al. 2005 Mutation analysis of p53, KRAS and B-RAF genes in colorectal cancer progression J Cell Physiol 204 484 488 1:CAS:528:DC%2BD2MXlvFCrsL0%3D 15702478 10.1002/jcp.20310 (Pubitemid 40934643)
85. C. Oliveira M. Pinto A. Duval, et al. 2003 B-RAF mutations characterize colon but no gastric cancer with mismatch repair deficiency Oncogene 22 9192 9196 1:CAS:528:DC%2BD3sXps1yitLc%3D 14668801 10.1038/sj.onc.1207061 (Pubitemid 38067995)
86. S. Ogino M. cantor T. Kawasaki, et al. 2006 CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies Gut 55 1000 1006 1:CAS:528:DC%2BD28XntF2mu7w%3D 16407376 10.1136/gut.2005.082933 (Pubitemid 43962613)
87. F. Perrone A. Lampis M. Orsenigo, et al. 2009 PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 84 90 1:STN:280:DC%2BD1M%2Fns1yktw%3D%3D 18669866 10.1093/annonc/mdn541
88. G. Finocchiaro F. Capuzzo E. Rossi, et al. 2008 Insulin-like growth factor receptor-1 (IGFR-1), MET, and B-RAF and primary resistance to cetuximab therapy in colorectal cancer patients J Clin Oncol 26s A4135
89. S. Artale A. Sartore-Bianchi S. Veronese, et al. 2008 Mutations of KRAS and B-RAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 26 4217 4219 18757341 10.1200/JCO.2008.18.7286
90. F. Di Nicolantonio M. Martini F. Molinari, et al. 2008 Wild-type B-RAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786 1:CAS:528:DC%2BD1MXotFemsA%3D%3D
91. S. Benvenuti A. Sartore-Bianchi F. Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathways impairs the response of metastatic colorectal cancer to anti-epidermal growth factor receptor antibodies therapies Cancer Res 67 2643 2648 1:CAS:528:DC%2BD2sXivV2ns7w%3D 17363584 10.1158/0008-5472.CAN-06-4158 (Pubitemid 46548951)
92. M. Jhawer S. Goel A.J. Wilson, et al. 2008 PIK3-CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 1:CAS:528:DC%2BD1cXjtFOhtro%3D 18339877 10.1158/0008-5472.CAN-07-5659
93. S. Vehlo C. Oliveira A. Ferreira, et al. 2005 The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 1649 1654 10.1016/j.ejca.2005.04.022 1:CAS:528:DC%2BD2MXmsVCmu7s%3D (Pubitemid 40981849)
94. S. Ogino K. Nosho G.J. Kirkner, et al. 2009 PIK3-CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 1477 1484 1:CAS:528:DC%2BD1MXksF2hsL4%3D 19237633 10.1200/JCO.2008.18.6544
95. A. Sartore-Bianchi M. Martini F. Molinari, et al. 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851 1857 1:CAS:528:DC%2BD1MXisFSrt7Y%3D 19223544 10.1158/0008-5472.CAN-08-2466
96. C. Blanco-Aparicio O. Renner J. Leal A. Carnero 2007 PTEN, more than the AKT pathway Carcinogenesis 28 1379 1386 1:CAS:528:DC%2BD2sXos12ju78%3D 17341655 10.1093/carcin/bgm052 (Pubitemid 47243536)
97. A. Carnero C. Blanco-Aparicio O. Renner, et al. 2008 The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications Curr Cancer Drug Targets 8 187 198 1:CAS:528:DC%2BD1cXmtFamt7g%3D 18473732 10.2174/156800908784293659 (Pubitemid 351688437)
98. J. Bing-Hua L. Ling-Zhi 2008 PI3K/PTEN signaling in tumorigenesis and angiogenesis Biochim Biophys Acta 1784 150 158
99. N.T. Nassif G.P. Lobo X. Wu, et al. 2004 PTEN mutations are common in sporadic microsatellite stable colorectal cancer Oncogene 23 617 628 1:CAS:528:DC%2BD2cXjtFKgsg%3D%3D 14724591 10.1038/sj.onc.1207059 (Pubitemid 38175018)
100. M. Frattini P. Saletti E. Romagnani, et al. 2007 PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 1139 1145 1:CAS:528:DC%2BD2sXhtFKktb7P 17940504 10.1038/sj.bjc.6604009 (Pubitemid 47587019)
101. F. Loupakis L. Pollina I. Stasi, et al. 2008 Evaluation of PTEN expression in colorectal cancer metastases and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment J Clin Oncol 26s A4003
102. A. Bardier J. Golmard J. Domont, et al. 2008 Coexpression of EGFR, pEGFR, VEGF, pVEGF, PTEN, pAKT and p21 in colorectal cancer patients can have IHC variability between metastases and primary tumors and for EGFR.targeted therapies, p21 and VEGF appear reliably as predictive factors of response J Clin Oncol 26s A22074
103. T. Colakoglu S. Yildirim F. Kayaselcuk, et al. 2008 Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg 195 719 725 1:CAS:528:DC%2BD1cXmsFKqtrs%3D 18440486 10.1016/j.amjsurg.2007. 05.061 (Pubitemid 351749462)
104. J.L. Merlin G. Perkins A. Lievre, et al. 2008 Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer J Clin Oncol 26s A4126
105. Bleeker FE, Felicioni L, Buttitta F et al (2008) AKT1(E17K) in human solid tumours. Oncogene [Epub ahead of print] PMID:18504432
106. M.S. Kim E.G. Jeong N.J. Yoo S.H. Lee 2008 Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukemias Br J Cancer 98 1553 1555
107. P. Saletti F. Molinari V. Martin, et al. 2008 Analysis of epidermal growth factor receptor (EGFR) downstream proteins in metastatic colorectal cancer patients: Comparison between primary tumor and related metastatic sites J Clin Oncol 26s A11075